Retatrutide TRIUMPH-1 Phase 3 shows 28% weight loss

Eli Lilly's retatrutide — a triple GLP-1 / GIP / glucagon receptor agonist — delivered 28.3% average body weight loss in the TRIUMPH-1 Phase 3 trial reported May 21, 2026. Participants on the 12 mg weekly dose lost approximately 70 pounds on average over 80 weeks from a baseline weight of 248.5 lbs — results that match bariatric surgery outcomes and exceed the best published semaglutide and tirzepatide data. The Lilly press release noted parallel improvements in osteoarthritis pain that exceeded the original trial design's expectations.

This is the largest weight-loss effect ever reported in a Phase 3 GLP-1-family trial, and it positions retatrutide as the leading candidate to push the metabolic-peptide ceiling higher than tirzepatide. Lilly indicated multiple additional Phase 3 readouts in 2026.

What happened

TRIUMPH-1 enrolled adults with overweight or obesity and a baseline weight of approximately 248.5 lbs, with treatment over 80 weeks at multiple dose levels including the highest tested at 12 mg weekly subcutaneous.

Headline results at the 12 mg dose:

Average weight loss: 28.3% of body weight
Average absolute weight loss: approximately 70 lbs
Trial duration: 80 weeks
Comparison framing: matches bariatric surgery outcomes

The press release also noted substantial improvement in osteoarthritis pain — a secondary endpoint that has implications well beyond pure weight loss, since the OA-obesity feedback loop drives a significant chunk of musculoskeletal disability.

Safety profile from the Scientific American coverage:

Approximately one-third of participants experienced nausea or diarrhea
About one-quarter reported constipation
10–25% experienced vomiting (dose-dependent)
Experts characterized the side-effect profile as "in line with expectations" for the GLP-1 family

Lilly is expected to file for FDA approval based on this and additional readouts. Seven additional Phase 3 readouts for retatrutide are expected in 2026.

Why it matters

For the strength-peptide and metabolic-health community, retatrutide's data shifts several conversations:

The "ceiling" of metabolic peptide effect just moved. Semaglutide produces ~15% weight loss; tirzepatide ~22%. Retatrutide producing 28% means the dose-response space for these compounds isn't fully explored. The biology has more room.

The triple-agonist thesis is validated. Adding glucagon agonism to GLP-1 + GIP appears to produce more weight loss than either single or dual agonism. Pharmacologists will continue probing this space.

The osteoarthritis benefit is notable. Strength and recovery athletes often deal with OA-spectrum joint issues. If retatrutide's OA benefit holds up, it adds a non-weight-loss reason to consider the class for some populations.

Lean-mass loss concerns remain. The TRIUMPH-1 readout focuses on total weight loss, not body composition specifics. If retatrutide's composition mirrors semaglutide and tirzepatide (~25–35% of weight loss from lean tissue), then the absolute lean loss in a 70-lb total drop is meaningful. The peptide-stacking logic for lean preservation becomes more relevant the bigger the total loss.

For the broader strength-peptide stacking framework see semaglutide + peptide stack: protecting lean mass on GLP-1 and tirzepatide vs semaglutide for body composition.

What to watch

The retatrutide story is mid-arc:

Seven additional Phase 3 readouts expected in 2026 (per Lilly press release). Watch for type 2 diabetes, cardiovascular outcomes, and additional subpopulation data.
FDA approval timeline — likely 2027–2028 based on typical post-Phase 3 review. Compounded availability may precede formal approval.
Pricing and access — Lilly's pricing decision will significantly affect uptake. Watch for direct-to-consumer pricing similar to Zepbound.
Body composition substudies — the lean-mass loss question deserves dedicated analysis. Watch for DEXA-based substudies in the broader Phase 3 program.
Competitive response — Novo Nordisk's CagriSema and other triple agonist candidates will move faster to keep pace.

Sources

Trial of next-gen weight-loss drug retatrutide brings it one step closer to FDA approval — Scientific American, May 21, 2026
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs — Eli Lilly investor relations